000 | 02073 a2200625 4500 | ||
---|---|---|---|
005 | 20250516035956.0 | ||
264 | 0 | _c20110823 | |
008 | 201108s 0 0 eng d | ||
022 | _a0392-856X | ||
040 |
_aNLM _beng _cNLM |
||
100 | 1 | _ade Menthon, Mathilde | |
245 | 0 | 0 |
_aInfliximab or rituximab for refractory Wegener's granulomatosis: long-term follow up. A prospective randomised multicentre study on 17 patients. _h[electronic resource] |
260 |
_bClinical and experimental rheumatology _c |
||
300 |
_aS63-71 p. _bdigital |
||
500 | _aPublication Type: Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't | ||
650 | 0 | 4 | _aAdult |
650 | 0 | 4 | _aAged |
650 | 0 | 4 |
_aAntibodies, Monoclonal _xadverse effects |
650 | 0 | 4 |
_aAntibodies, Monoclonal, Murine-Derived _xadverse effects |
650 | 0 | 4 | _aChi-Square Distribution |
650 | 0 | 4 | _aDrug Resistance |
650 | 0 | 4 | _aDrug Substitution |
650 | 0 | 4 | _aFemale |
650 | 0 | 4 | _aFrance |
650 | 0 | 4 |
_aGranulomatosis with Polyangiitis _xdiagnosis |
650 | 0 | 4 | _aHumans |
650 | 0 | 4 |
_aImmunosuppressive Agents _xadverse effects |
650 | 0 | 4 | _aInfliximab |
650 | 0 | 4 | _aKaplan-Meier Estimate |
650 | 0 | 4 | _aMale |
650 | 0 | 4 | _aMiddle Aged |
650 | 0 | 4 | _aPatient Selection |
650 | 0 | 4 | _aProspective Studies |
650 | 0 | 4 | _aRecurrence |
650 | 0 | 4 | _aRemission Induction |
650 | 0 | 4 | _aRisk Assessment |
650 | 0 | 4 | _aRisk Factors |
650 | 0 | 4 | _aRituximab |
650 | 0 | 4 | _aSeverity of Illness Index |
650 | 0 | 4 | _aTime Factors |
650 | 0 | 4 | _aTreatment Outcome |
650 | 0 | 4 | _aYoung Adult |
700 | 1 | _aCohen, Pascal | |
700 | 1 | _aPagnoux, Christian | |
700 | 1 | _aBuchler, Matthias | |
700 | 1 | _aSibilia, Jean | |
700 | 1 | _aDétrée, Frédérick | |
700 | 1 | _aGayraud, Martine | |
700 | 1 | _aKhellaf, Mehdi | |
700 | 1 | _aPenalba, Christian | |
700 | 1 | _aLegallicier, Bruno | |
700 | 1 | _aMouthon, Luc | |
700 | 1 | _aGuillevin, Loïc | |
773 | 0 |
_tClinical and experimental rheumatology _gvol. 29 _gno. 1 Suppl 64 _gp. S63-71 |
|
999 |
_c20848490 _d20848490 |